AdvaMed® State Policy Briefing: PFAS – Background, Basics, and State Policy

AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it. 

Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Join us May 30, 11:00am–12:30pm ET.

WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.

WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.

Washington, D.C.–AdvaMed President and CEO Scott Whitaker released the following statement upon re-introduction of bipartisan legislation aimed at accelerating Medicare coverage for breakthrough medtech and diagnostics. The Ensuring Patient Access to Critical Breakthrough Products Act, introduced by Senators Todd Young (R-Ind.) and Alex Padilla (D-Calif.), allows Medicare beneficiaries with life-threatening or debilitating diseases or conditions access to groundbreaking medical innovations, designated as breakthrough devices to treat unmet needs and already authorized by the FDA.

At AdvaMed, we’re proud to be recognized for our work on behalf of the medtech community – and we’re especially grateful when that recognition comes from respected voices like Kwame Ulmer of MedTech Impact Partners and our colleagues at Orthogonal. 

Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling for reciprocal “zero for zero” tariffs between the two countries.

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.